Amphastar Pharmaceuticals, Inc. (AMPH): Price and Financial Metrics


Amphastar Pharmaceuticals, Inc. (AMPH): $29.36

-0.85 (-2.81%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

AMPH POWR Grades

  • Value is the dimension where AMPH ranks best; there it ranks ahead of 88.65% of US stocks.
  • The strongest trend for AMPH is in Growth, which has been heading down over the past 178 days.
  • AMPH ranks lowest in Momentum; there it ranks in the 12th percentile.

AMPH Stock Summary

  • Of note is the ratio of AMPHASTAR PHARMACEUTICALS INC's sales and general administrative expense to its total operating expenses; merely 23.6% of US stocks have a lower such ratio.
  • AMPH's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of 25.26% of US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, AMPHASTAR PHARMACEUTICALS INC is reporting a growth rate of 106.79%; that's higher than 86.54% of US stocks.
  • If you're looking for stocks that are quantitatively similar to AMPHASTAR PHARMACEUTICALS INC, a group of peers worth examining would be GNTX, NVMI, MTSI, EYEN, and ALRM.
  • AMPH's SEC filings can be seen here. And to visit AMPHASTAR PHARMACEUTICALS INC's official web site, go to www.amphastar.com.

AMPH Valuation Summary

  • AMPH's price/sales ratio is 3; this is 40% lower than that of the median Healthcare stock.
  • Over the past 103 months, AMPH's price/sales ratio has gone up 1.3.

Below are key valuation metrics over time for AMPH.

Stock Date P/S P/B P/E EV/EBIT
AMPH 2022-12-02 3.0 2.9 18.9 13.8
AMPH 2022-12-01 3.0 2.9 18.8 13.7
AMPH 2022-11-30 2.9 2.8 18.5 13.4
AMPH 2022-11-29 2.9 2.8 18.4 13.4
AMPH 2022-11-28 2.9 2.8 18.3 13.3
AMPH 2022-11-25 2.9 2.8 18.3 13.3

AMPH Growth Metrics

    Its 5 year net income to common stockholders growth rate is now at 393.92%.
  • Its year over year cash and equivalents growth rate is now at 69.75%.
  • The 2 year net cashflow from operations growth rate now stands at 168.81%.
AMPH's revenue has moved up $237,100,000 over the prior 52 months.

The table below shows AMPH's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 484.851 114.396 77.233
2022-06-30 476.92 96.59 90.907
2022-03-31 455.116 125.934 81.328
2021-12-31 437.768 97.994 62.116
2021-09-30 412.802 74.446 36.083
2021-06-30 384.035 80.684 10.454

AMPH's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • AMPH has a Quality Grade of C, ranking ahead of 66.19% of graded US stocks.
  • AMPH's asset turnover comes in at 0.601 -- ranking 59th of 680 Pharmaceutical Products stocks.
  • VTVT, MTEX, and BBI are the stocks whose asset turnover ratios are most correlated with AMPH.

The table below shows AMPH's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.601 0.431 0.042
2021-03-31 0.591 0.411 0.012
2020-12-31 0.579 0.410 0.012
2020-09-30 0.568 0.415 0.026
2020-06-30 0.570 0.415 0.017
2020-03-31 0.558 0.421 0.160

AMPH Price Target

For more insight on analysts targets of AMPH, see our AMPH price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $22.75 Average Broker Recommendation 1.75 (Moderate Buy)

AMPH Stock Price Chart Interactive Chart >

Price chart for AMPH

AMPH Price/Volume Stats

Current price $29.36 52-week high $44.46
Prev. close $30.21 52-week low $20.17
Day low $29.32 Volume 227,599
Day high $30.15 Avg. volume 397,853
50-day MA $29.14 Dividend yield N/A
200-day MA $32.72 Market Cap 1.42B

Amphastar Pharmaceuticals, Inc. (AMPH) Company Bio


Amphastar Pharmaceuticals focuses on the development, manufacture, marketing, and sale of generic and proprietary injectable and inhalation products. It operates in two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients. The company was founded in 1996 and is based in Rancho Cucamonga, California.


AMPH Latest News Stream


Event/Time News Detail
Loading, please wait...

AMPH Latest Social Stream


Loading social stream, please wait...

View Full AMPH Social Stream

Latest AMPH News From Around the Web

Below are the latest news stories about AMPHASTAR PHARMACEUTICALS INC that investors may wish to consider to help them evaluate AMPH as an investment opportunity.

Amphastar Pharmaceuticals to Present at the Piper Sandler 34th Annual Healthcare Conference

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Tony Marrs, Sr. Vice President Regulatory Affairs and Clinical Operations, will participate in an Analyst-Moderated fireside chat at the Piper Sandler 34th Annual Healthcare Conference on November 30th, 2022 at 11:00 am Eastern Time. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com.

Yahoo | November 22, 2022

Amphastar Pharmaceuticals to Present at the 2022 Jefferies London Healthcare Conference

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Jacob Liawatidewi, Executive V.P. of Corporate Administration Center, will participate in an Analyst-Moderated fireside chat at the 2022 Jefferies London Healthcare Conference on November 16th , 2022 at 3:50 pm Greenwich Mean Time. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com .

Yahoo | November 10, 2022

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Cara Therapeutics (CARA) and Amphastar Pharmaceuticals (AMPH)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Cara Therapeutics (CARA – Research Report) and Amphastar Pharmaceuticals (AMPH – Research Report). Cara Therapeutics (CARA) In a report released today, Joseph Stringer from Needham reiterated a Buy rating on Cara Therapeutics, with a price target of $26.00. The company's shares closed last Monday at $9.34. According to TipRanks.

Brian Anderson on TipRanks | November 8, 2022

Amphastar Pharmaceuticals Q3 2022 Earnings Preview

  • Amphastar Pharmaceuticals (NASDAQ:AMPH) is scheduled to announce Q3 earnings results on Monday, November 7th, after market close.

Amphastar Pharmaceuticals (AMPH) Q3 Earnings Meet Estimates

Amphastar (AMPH) delivered earnings and revenue surprises of 0% and 4.81%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 7, 2022

Read More 'AMPH' Stories Here

AMPH Price Returns

1-mo -1.34%
3-mo 3.53%
6-mo -23.32%
1-year 43.85%
3-year 55.18%
5-year 60.17%
YTD 26.06%
2021 15.81%
2020 4.25%
2019 -3.07%
2018 3.43%
2017 4.45%

Continue Researching AMPH

Want to see what other sources are saying about Amphastar Pharmaceuticals Inc's financials and stock price? Try the links below:

Amphastar Pharmaceuticals Inc (AMPH) Stock Price | Nasdaq
Amphastar Pharmaceuticals Inc (AMPH) Stock Quote, History and News - Yahoo Finance
Amphastar Pharmaceuticals Inc (AMPH) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7605 seconds.